A 450-task benchmark built from real CVEs shows even the best AI coding agent writes code that's both working and secure only ...
This project implements the Lox interpreter from Crafting Interpreters by Robert Nystrom using Kotlin. test-output.txt contains my unit testing results Chapter 4: Implemented a scanner that converts ...
Recursive Flint is a 40B MoE local coding model with 2.5B active parameters, scoring 74.2% on SWE-bench Verified.
Startup Recursive has released Flint, a free, laptop-sized coding model built largely by its own AI research system, as an early test of AI that improves itself.
The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest ...
As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a reality.
“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...
The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.
Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated ...